Key Takeaways From ASH 2023: Emerging Trends in Hematologic Oncology
Julie M. Vose, MD, MBA, gave a brief overview of the 2023 American Society of Hematology Annual Meeting & Exposition, as well as what to be on the lookout for in 2024.
Strategy for Reducing Obesity May Mitigate Advanced Breast Cancer Diagnoses
Screening frequency appears to be a weak risk factor for advanced breast cancer, with obesity in post-menopausal and dense breasts in pre-menopausal patients being more prominent factors.
BST02 Receives FDA Fast Track Designation in Liver Cancer Management
Investigators are assessing the safety, tolerability, and initial efficacy of BST02 in those with advanced or metastatic liver cancer as part of a phase 1 trial.
FDA Grants Orphan Drug Designation to NT-I7 in Advanced Pancreatic Cancer
Treatment with NT-I7 may boost the immune system and enhance antitumor activity in patients with pancreatic cancer and other solid tumors.
EMA Validates Tisotumab Vedotin Marketing Application in Cervical Cancer
Tisotumab vedotin may become the first antibody drug conjugate to receive marketing authorization in the European Union as a treatment for those with cervical cancer.
Unraveling Resistance and Heterogeneity in Mantle Cell Lymphoma Management
The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.
Person-First Language May Mitigate Stigmatization in Lung Cancer Screening
Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.
WHO Survey Determines Increased Cancer Burden Over Next 25 Years
A 77% increase in the risk of developing cancer by 2050 was determined by the World Health Organization in a recent survey.
Pembrolizumab Combo Yields Efficacy in Advanced Urothelial Carcinoma
Combining pembrolizumab with cabozantinib produces encouraging efficacy in platinum-ineligible patients with advanced urothelial carcinoma, says Rohit K. Jain, MD, MPH.
Enfortumab Vedotin Combo Improves Outcomes in Urothelial Cancer Subgroups
Benefits with enfortumab vedotin plus pembrolizumab in prespecified patient subgroups with urothelial carcinoma in the EV-302 trial appear to be consistent with outcomes in the overall study population.
Liso-Cel Yields Long-Lasting Complete Responses in Heavily Pretreated MCL
Treatment with liso-cel appears to result in clinically meaningful activity across several subgroups of patients with mantle cell lymphoma, including those with high-risk features.
Bevacizumab Combo Does Not Improve Outcomes in Metastatic Nonsquamous NSCLC
Adding bevacizumab to atezolizumab plus carboplatin and pemetrexed appears to be tolerable among patients with metastatic nonsquamous non–small cell lung cancer.
EMA Accepts Marketing Application for Linvoseltamab in R/R Multiple Myeloma
Findings from the phase 1/2 LINKER-MM1 trial support the marketing authorization application for linvoseltamab in the management of relapsed/refractory multiple myeloma.
MCL Experts Give Overview of Expected Trends in the Field
Considering tumor genomics, personalization of therapy, and the use of biomarkers, experts in the mantle cell lymphoma field discuss how to best utilize these strategies to improve treatment outcomes.
Expert Discusses Strategies for Managing BCG Shortage in Bladder Cancer
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Ziftomenib/Standard Therapy Yields 100% CR Rate in NPM1+ or KMT2A+ AML Subset
Most patients with acute myeloid leukemia appear to remain on treatment with ziftomenib plus standard-of-care therapy in the phase 1 KOMET-007 trial.
TOETVA Surgical Approach Appears Efficacious for Benign Thyroid Tumors
Patients with benign thyroid tumors resected with a transoral endoscopic thyroidectomy vestibular approach have less complications vs those treated with a standard surgical approach.
FDA Gives Priority Review to Afami-Cel in Advanced Synovial Sarcoma
Data from the phase 2 SPEARHEAD-1 trial support the biologics license application for afami-cel as a treatment for patients with advanced synovial sarcoma.
Updated AUA/SUO Guidelines May Improve NMIBC Evaluation and Management
Clinical practice guideline amendments detail novel urinary biomarkers and agents that may improve Bacillus Calmette-Guerin efficacy in the management of non-muscle invasive bladder cancer.
Hispanic Population Appears Underrepresented in Pediatric Cancer Trials
FDA initiatives such as the Food and Drug Omnibus Reform Act will set goals and specify measures for improving representation in pediatric cancer clinical studies.
Simeone Named Director of UCSD Moores Cancer Center: “It’s an Opportunity of a Lifetime”
Starting April 1, 2024, Diane Simeone will be the new director of UCSD Moores Cancer Center.
FDA Receives sNDA for Daratumumab Combo in Newly Diagnosed Multiple Myeloma
Findings from the phase 3 PERSEUS trial support the supplemental New Drug Application for the daratumumab and hyaluronidase-fihj combination in transplant-eligible newly diagnosed multiple myeloma.
Digital PROs May Identify Multiple Myeloma Subgroup Fit for Bortezomib
Patients with multiple myeloma appear to feel confident in being able to report adverse effects associated with bortezomib independently via digital tools.
Iruplinalkib Improves PFS Vs Crizotinib in Advanced ALK+ NSCLC
Data from the phase 3 INSPIRE trial may support iruplinalkib as a new treatment option for those with advanced ALK-positive non–small cell lung cancer.
CHMP Expresses Positive Opinion for Ide-Cel in R/R Multiple Myeloma
A positive CHMP opinion may lead to an approval of idecabtagene vicleucel in the European Union for patients with relapsed/refractory multiple myeloma.
Talazoparib/Enzalutamide Improves Long-Term QOL in Metastatic CRPC
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
FDA Grants Priority Review to Liso-cel in Relapsed/Refractory MCL/FL
Japan’s Ministry of Health, Labour, and Welfare also accepted a supplemental new drug application for lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.
Daratumumab Combo Improves PFS in Newly Diagnosed Multiple Myeloma
Adding daratumumab to VRd induction and consolidation therapy plus lenalidomide maintenance provides a benefit with respect to MRD-negative status among patients with multiple myeloma.
Postoperative IMRT Improves RFS in Hepatocellular Carcinoma
At 1 and 2 years, patients with hepatocellular carcinoma and narrow surgical margins experienced encouraging recurrence-free survival rates following adjuvant radiotherapy in the phase 2 RAISE trial.
FDA Grants Priority Review to Alectinib for ALK+ NSCLC
The FDA will review the supplemental biologics license application for alectinib based on data from the phase 3 ALINA study.
